Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + bevacizumab + pemetrexed + carboplatin
- Development stage
- Phase 2
- Lead developer
- Hunan Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational treatment regimen is being evaluated in a Phase 2 clinical trial (NCT05266846) at the Hunan Province Tumor Hospital for the treatment of metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) in patients who have progressed after first-line alectinib therapy. The regimen consists of the anti-PD-1 monoclonal antibody pembrolizumab, the anti-VEGF monoclonal antibody bevacizumab, and a chemotherapy backbone of pemetrexed and carboplatin. By combining immunotherapy, anti-angiogenic therapy, and cytotoxic chemotherapy, the regimen aims to overcome resistance to ALK tyrosine kinase inhibitors (TKIs) and improve outcomes in advanced lung adenocarcinoma with persistent 5'ALK.
- Other names
- Pembrolizumab plus Bevacizumab plus Pemetrexed plus CarboplatinChemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab
02
Targets
DNADHFR (Dihydrofolate reductase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on pembrolizumab + bevacizumab + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + bevacizumab + pemetrexed + carboplatin.